Earnings ·
Neurocrine Biosciences reported second-quarter 2026 financial results with total revenues of $959 million, a 39%…
NBIXNeurocrine Biosciences Inc
Neurocrine Biosciences reported second-quarter 2026 financial results with total revenues of $959 million, a 39% increase year-over-year from $688 million. GAAP diluted earnings per share were $1.39, compared to $1.06 in the prior year period. The company raised its full-year 2026 INGREZZA net product sales guidance to $2.825–$2.875 billion from a previous range of $2.7–$2.8 billion. Neurocrine completed its acquisition of Soleno Therapeutics in May 2026 for $2.9 billion, adding VYKAT XR to its portfolio, and entered into a $1.0 billion senior secured revolving credit facility. The biopharmaceutical company discovers, develops, and commercializes treatments for neurological, psychiatric, endocrine, and immunological disorders.